Valeant hepatitis C drug misses goal, shares dive (Hepatitis C Infection)

Valeant hepatitis C drug misses goal, shares dive
Reuters - Mar 21, 2006... Valeant Pharmaceuticals International (VRX.N: Quote, Profile, Research) said on Tuesday a late-stage trial showed its chronic hepatitis C treatment was not as ...

Cuban Combined Therapy Against Chronic Hepatitis C
Ahora.cu, Cuba - Mar 23, 2006A Cuban combination therapy for the treatment of chronic Hepatitis C is to be put on the market by the Heber Biotec SA company in Latin America, Asia, Africa ...

(PRN) - Demographic Study Finds the Digital Divide is Closing ... ...
Bolsamania.com, Spain - Mar 14, 2006... Reports Positive Interim Results of Phase 2 Trial of Albuferon(TM) In Combination With Ribavirin In Treatment-Experienced Patients With Chronic Hepatitis C ...

Novelos Therapeutics Closes $15 Million Private Placement
International News Service, Australia - Mar 7, 2006... NOV-002 in lung cancer, in addition to our other clinical development programs, including chemotherapy-resistant ovarian cancer and chronic hepatitis C with NOV ...

Human Genome Sciences up on drug outlook
BusinessWeek - Mar 1, 2006... on Wednesday after the company presented at an investor conference and provided an "upbeat" outlook for Albuferon, a possible treatment for chronic hepatitis C ...